Benjamin Zuckerman

Benjamin Zuckerman

Auto-generated profile, based on publicly available information

Benjamin Zuckerman

Centre for Rheumatic Diseases, King’s College London , London

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 September 2022 in Diabetic Medicine
Verified
Journal Article
Open access
VKVaro Kirthi
Varo Kirthi
KRKate I. Reed
Kate I. Reed
KAKomeil Alattar
Komeil Alattar
BZBenjamin P. Zuckerman
Benjamin P. Zuckerman
CBCatey Bunce
Catey Bunce
TJTimothy L. Jackson
Timothy L. Jackson
Aim: To explore if novel non‐invasive diagnostic technologies identify early small nerve fibre and retinal neurovascular pathology in prediabetes.Methods: Participants with normoglycaemia, prediabetes or type 2 diabetes underwent an exploratory cross‐sectional analysis with optical coherence tomography angiography (OCT‐A), handheld electroretinography (ERG), corneal confocal microscopy (CCM) and evaluation of electrochemical skin conductance (ESC).Results: Seventy‐five participants with normoglycaemia (n = 20), prediabetes (n = 29) and type 2 diabetes (n = 26) were studied. Compared with normoglycaemia, mean peak ERG amplitudes of retinal responses at low (16‐Td·s: 4.05 μV, 95% confidence interval [95% CI] 0.96–7.13) and high (32‐Td·s: 5·20 μV, 95% CI 1.54–8.86) retinal illuminance were lower in prediabetes, as were OCT‐A parafoveal vessel densities in superficial (0.051 pixels/mm2, 95% CI 0.005–0.095) and deep (0.048 pixels/mm2, 95% CI 0.003–0.093) retinal layers. There were no differences in CCM or ESC measurements between these two groups. Correlations between HbA1c and peak ERG amplitude at 32‐Td·s (r = −0.256, p = 0.028), implicit time at 32‐Td·s (r = 0.422, p < 0.001) and 16‐Td·s (r = 0.327, p = 0.005), OCT parafoveal vessel density in the superficial (r = −0.238, p = 0.049) and deep (r = −0.3, p = 0.017) retinal layers, corneal nerve fibre length (CNFL) (r = −0.293, p = 0.017), and ESC‐hands (r = −0.244, p = 0.035) were observed. HOMA‐IR was a predictor of CNFD (β = −0.94, 95% CI −1.66 to −0.21, p = 0.012) and CNBD (β = −5.02, 95% CI −10.01 to −0.05, p = 0.048).Conclusions: The glucose threshold for the diagnosis of diabetes is based on emergent retinopathy on fundus examination. We show that both abnormal retinal neurovascular structure (OCT‐A) and function (ERG) may precede retinopathy in prediabetes, which require confirmation in larger, adequately powered studies.

14 November 2025 in Rheumatology
Verified
Journal Article
Open access
KBKatie Bechman
Katie Bechman
KSKaiyang Song
Kaiyang Song
AAAbhishek Abhishek
Abhishek Abhishek
MAMaryam Adas
Maryam Adas
AAAlison Ahmed
Alison Ahmed
BGBritish Society for Rheumatology Guidelines Steering Group
British Society for Rheumatology Guidelines Steering Group

6 December 2021 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
PJPaul D. Jewell
Paul D. Jewell
KBKate Bramham
Kate Bramham
JGJames Galloway
James Galloway
FPFrank Post
Frank Post
SNSam Norton
Sam Norton
ELEirini Lioudaki
Eirini Lioudaki
An amendment to this paper has been published and can be accessed via the original article.

24 February 2025 in Rheumatology
Verified
Journal Article
Open access
BZBenjamin P Zuckerman
Benjamin P Zuckerman
MGMark Gibson
Mark Gibson
RRRitika Roy
Ritika Roy
MHMark Hughes
Mark Hughes
DMDaksh Mehta
Daksh Mehta
JGJames Galloway
James Galloway
Objectives: To estimate the association between abatacept use and the incidence of malignancy excluding non-melanomatous skin cancers (NMSCs). Methods: Systematic database searches were performed, to April 2024, to identify phase II/III/IV randomized clinical trials (RCTs), long-term extension (LTE) and observational cohort studies of abatacept in people with rheumatoid arthritis and psoriatic arthritis. Network and pairwise meta-analyses were performed to estimate incidence rate ratios (IRRs) for malignancy excluding NMSC, comparing abatacept with placebo and tumour necrosis factor inhibitors (TNFi) in RCT/LTE studies. Pairwise meta-analyses evaluated the same outcome in observational studies, comparing abatacept with conventional synthetic DMARDs (csDMARDs) and biologic/targeted synthetic disease modifying antirheumatic drugs (b/tsDMARDs). Results: In 18 eligible RCTs and 10 LTE studies, there were 15 535 person-years of exposure to abatacept, 1495 to placebo and 733 to TNFi. In network meta-analyses of combined RCT/LTE data, the incidence of all malignancies excluding NMSCs was not significantly different between abatacept and placebo (IRR 0.58; 95% CI 0.32–1.09) or TNFi (IRR 0.72; 95% 0.27–1.87). In observational data, the incidence of malignancy was higher with abatacept, relative to other b/tsDMARDs (IRR 1.21; 95% CI 1.15–1.28), but not significantly different compared with csDMARDs (IRR 0.97; 95% CI 0.90–1.06). Conclusions: Abatacept was associated with a higher incidence of malignancy compared with other b/tsDMARDs in observational studies, but not when compared with placebo or TNFi in RCT/LTE data. Further pharmacovigilance data is essential to help elucidate whether abatacept modifies cancer risk. PROSPERO registration number: CRD42023382314.

1 November 2024 in Rheumatology
Verified
Journal Article
Open access
PDF file
MRMark D Russell
Mark D Russell
ZYZijing Yang
Zijing Yang
NDNiamh Dooley
Niamh Dooley
MGMark Gibson
Mark Gibson
BZBenjamin Zuckerman
Benjamin Zuckerman
JGJames Galloway
James Galloway
Objective: The objective of this study was to evaluate temporal and regional variation in biologic and targeted synthetic DMARD (b/tsDMARD) initiation for RA in England and Wales. Methods: An observational cohort study was conducted for people with RA enrolled in the National Early Inflammatory Arthritis Audit (NEIAA) between May 2018 and April 2022 who had 12-month follow-up data available. Temporal trends in escalation to b/tsDMARDs within 12 months of initial rheumatology assessment were explored, including comparisons before and after publication (July 2021) of national guidelines that lowered the threshold for b/tsDMARD initiation to include moderate-severity RA. Case-mix–adjusted, mixed-effects regression was used to evaluate regional and hospital-level variation in b/tsDMARD initiation. Results: Of 6098 RA patients with available follow-up, 508 (8.3%) initiated b/tsDMARDs within 12 months of initial assessment. b/tsDMARD escalation increased marginally towards the end of the study period (9.2% in May 2021/22); however, no significant differences were evident after guidelines were published permitting b/tsDMARD use for moderate-severity RA. The proportion of individuals escalated to b/tsDMARDs varied considerably between regions, ranging from 5.1% in Wales to 10.7% in North-West England. Following case-mix adjustment, the intraclass correlation (ICC) for hospitals within regions was 0.17, compared with a between-region ICC of 0.0, suggesting that the observable regional variation reflected hospital-level differences rather than systematic differences between regions themselves. Conclusion: There is marked variation in escalation to b/tsDMARDs for people newly diagnosed with RA throughout England and Wales, despite a universal health-care system. These disparities must be addressed if we are to deliver equitable access to b/tsDMARDs, regardless of geography.

28 May 2025 in Journal of Open Source Software
Verified
Journal Article
Open access
PDF file
AWAlasdair Neil Warwick
Alasdair Neil Warwick
BZBenjamin Zuckerman
Benjamin Zuckerman
CUChuin Ying Ung
Chuin Ying Ung
RLRobert Luben
Robert Luben
AOAbraham Olvera-Barrios
Abraham Olvera-Barrios
The Genotype-Tissue Expression (GTEx) project (GTEx Consortium, 2013, 2020) is a comprehensive public resource for studying tissue-specific gene expression and regulation in human tissues. Through systematic analysis of RNA sequencing data from 54 non-diseased tissue sites across nearly 1000 individuals, GTEx provides crucial insights into the relationship between genetic variation and gene expression. This data is accessible through the GTEx Portal API (GTEx Consortium, 2023), enabling programmatic access to human gene expression data.